Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETNBNASDAQ:HROWNASDAQ:MLYSNASDAQ:THRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89BIO$10.14+0.4%$9.26$4.16▼$11.84$1.48B1.281.52 million shs1.94 million shsHROWHarrow$31.78+4.0%$28.32$20.85▼$59.23$1.16B0.41494,461 shs257,698 shsMLYSMineralys Therapeutics$14.53+1.6%$14.94$8.24▼$18.38$947.65M-0.3546,669 shs349,918 shsTHRDThird Harmonic Bio$5.43+0.2%$0.00$0.00▼$0.00$245.04M2.12223,747 shs37,814 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89BIO+0.40%+1.91%-0.29%+75.74%+35.56%HROWHarrow+3.96%+1.37%+8.32%+35.12%+47.10%MLYSMineralys Therapeutics+1.57%+3.75%-10.23%+17.14%+19.55%THRDThird Harmonic Bio+0.18%0.00%+3.63%+51.82%-54.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETNB89BIO1.9373 of 5 stars3.51.00.00.02.30.80.6HROWHarrow2.7063 of 5 stars3.52.00.00.02.22.50.6MLYSMineralys Therapeutics2.1746 of 5 stars3.41.00.00.01.44.20.0THRDThird Harmonic Bio0.7379 of 5 stars1.04.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETNB89BIO 3.00Buy$26.43160.64% UpsideHROWHarrow 3.00Buy$61.4093.20% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25122.03% UpsideTHRDThird Harmonic Bio 2.00Hold$5.00-7.92% DownsideCurrent Analyst Ratings BreakdownLatest THRD, MLYS, HROW, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/12/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.006/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.006/10/2025HROWHarrowWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/12/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$57.00 ➝ $60.005/10/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETNB89BION/AN/AN/AN/A$3.34 per shareN/AHROWHarrow$199.61M5.84$0.14 per share232.19$1.95 per share16.30MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ATHRDThird Harmonic BioN/AN/AN/AN/A$6.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)HROWHarrow-$17.48M-$0.56N/A79.45N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)THRDThird Harmonic Bio-$45.47M-$0.620.00N/AN/AN/A-19.27%-18.67%N/ALatest THRD, MLYS, HROW, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million5/8/2025Q1 2025THRDThird Harmonic Bio-$0.26-$0.35-$0.09-$0.35N/AN/A5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETNB89BION/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ATHRDThird Harmonic BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETNB89BIO0.0618.0318.03HROWHarrow2.010.910.85MLYSMineralys TherapeuticsN/A26.4826.48THRDThird Harmonic BioN/A54.1054.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETNB89BION/AHROWHarrow72.76%MLYSMineralys Therapeutics84.46%THRDThird Harmonic Bio93.95%Insider OwnershipCompanyInsider OwnershipETNB89BIO2.60%HROWHarrow15.16%MLYSMineralys Therapeutics25.56%THRDThird Harmonic Bio7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETNB89BIO40145.98 million142.19 millionOptionableHROWHarrow18036.69 million31.12 millionOptionableMLYSMineralys Therapeutics2865.18 million48.52 millionOptionableTHRDThird Harmonic BioN/A45.13 million41.61 millionOptionableTHRD, MLYS, HROW, and ETNB HeadlinesRecent News About These CompaniesThird Harmonic Bio Inc News (THRD) - Investing.comJuly 3 at 6:21 PM | investing.comThird Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335June 12, 2025 | globenewswire.comNortheast Dominates 2025 Highest Income Rankings, Study Says: See Where Your State StandsJune 9, 2025 | msn.comThird Harmonic Bio plans to liquidate the company, sell urticaria treatmentApril 14, 2025 | msn.comThird Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s ShatteredApril 14, 2025 | msn.comThird Harmonic Bio Announces Plan of Liquidation and DissolutionApril 14, 2025 | globenewswire.comThird Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 27, 2025 | globenewswire.comThird Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 4, 2025 | zacks.comThird Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?February 14, 2025 | zacks.comDown -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)February 14, 2025 | zacks.comThird Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic UpdateFebruary 11, 2025 | globenewswire.comThird Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx ConferenceNovember 25, 2024 | globenewswire.comApple making foray into smart home IP camera market, says analyst Ming-Chi KuoNovember 13, 2024 | finance.yahoo.comUpdates to the British Virgin Islands Anti-Money Laundering regime and changes for MLROsNovember 12, 2024 | jdsupra.comWall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to TradeNovember 11, 2024 | zacks.com(LEAD) Netmarble swings to black in Q3 on steady-selling titlesNovember 8, 2024 | msn.comNissan plans 9,000 job cuts, slashes annual profit outlookNovember 7, 2024 | msn.comThird Harmonic Bio to Participate in Upcoming Investor Conferences in NovemberNovember 7, 2024 | globenewswire.comSarepta Therapeutics (SRPT) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comInterest rates live updates: Bank of England base rate cut to help slash mortgage billsNovember 7, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTHRD, MLYS, HROW, and ETNB Company Descriptions89BIO NASDAQ:ETNB$10.14 +0.04 (+0.40%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$10.14 -0.01 (-0.05%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Harrow NASDAQ:HROW$31.78 +1.21 (+3.96%) As of 07/3/2025 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Mineralys Therapeutics NASDAQ:MLYS$14.52 +0.23 (+1.57%) Closing price 07/3/2025 03:09 PM EasternExtended Trading$14.52 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Third Harmonic Bio NASDAQ:THRDTF Financial Corporation is a savings and loan holding company. The Company's direct and indirect subsidiaries include Third Federal Bank (the Bank), Teragon Financial Corporation, Penns Trail Development Corporation and Third Delaware Corporation. The Bank is a community oriented Pennsylvania stock savings bank offering a variety of financial services to meet the needs of the communities it serves. As of December 31, 2011 the Bank operated fourteen branch offices in Bucks and Philadelphia Counties, Pennsylvania and in Mercer County, New Jersey. During the year ended December 31, 2011, the Company's subsidiary, TF Investments Corporation merged into TF Financial Corporation. In July 2013, the Company acquired Roebling Financial Corp, Inc. (Roebling) and its wholly-owned subsidiary, Roebling Bank. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
